Xiamen Amoytop Biotech Co. starts sales of long-acting Paigebin PEGinterferon-2b

The injectable biologic is directed towards the treatment of chronic viral hepatitis.

China Bio news release, November 1, 2016

Xiamen Amoytop Biotech Co. starts sales of long-acting Paigebin PEGinterferon-2b
Scroll to top